Abstract: The histologic distinction between bronchioloalveolar carcinoma and other adenocarcinomas is tissue invasion. The clinical importance of lung adenocarcinoma invasion is supported by several recent studies indicating that the risk of death in nonmucinous bronchioloalveolar carcinoma is significantly lower than that of pure invasive tumors and in tumors with greater than 0.5 cm of fibrosis or linear invasion. Using microarray gene expression profiling of human tumors, dysregulation of transforming growth factor-β signaling was identified as an important mediator of tumor invasion. Subsequent studies showed that the CC chemokine regulated on activation, normal T cell expressed, and presumably secreted was up-regulated in invasive tumors and was required for invasion in cells with repressed levels of the transforming growth factor-β type II receptor. Taken together, these studies illustrate how information gained from global expression profiling of tumors can be used to identify key pathways and genes mediating tumor growth, invasion, and metastasis.

Key Words: Lung adenocarcinoma, Bronchioloalveolar carcinoma, Invasion, TGF-beta, TGFβRII, RANTES, Lung cancer genomics.

(J Thorac Oncol. 2010;5: 153–157)

The World Health Organization subclassifies adenocarcinoma (AC) based on predominant cell morphology and growth pattern. The histologic distinction between bronchioloalveolar carcinoma (BAC) and other ACs is tissue invasion. BAC tumor cells are cuboidal to columnar, with or without mucin, that grow in a noninvasive fashion along alveolar walls. Invasion, defined as tumor disruption of the alveolar basement membrane, is present in 20% of ACs that had an invasive area greater than 5 mm. Similarly, among 178 patients with resected lung AC, we found 5-year survival rates of 100% and 90% for patients with BAC or tumors with invasive length less than 6 mm, respectively.

Recent clinical reports suggest that the prognosis and radiographic appearance of AC is unique and may support modifying the clinical approach to lung ACs according to histologic subtype. Metastases to lymph nodes and extrathoracic organs are unusual in nonmucinous BAC. The mean 5-year survival for stage I BAC and other ACs is 81 and 55%, respectively. Recent reports suggest that for stage IA BAC, limited resections rather than lobectomy, which is the current standard resection for stage IA AC, may be curative.

Lung adenocarcinoma invasion is associated with clinical outcomes. The clinical importance of lung AC invasion is supported by several recent studies, indicating that the risk of death in nonmucinous BAC is significantly lower than that of pure invasive tumors and in tumors with greater than 0.5 cm of fibrosis or linear invasion. In 200 cases of ACs (diameter <3 cm), Yokose et al.3 reported no deaths among 66 BAC cases. In 178 patients with resected lung AC, we found 5-year survival rates of 100% and 90% for patients with BAC or tumors with invasive length less than 6 mm, respectively.

Together, these studies suggest that noninvasive tumors are biologically indolent and that invasion increases the risk of metastatic disease and death in solitary mixed subtype tumors.

Invasion is the first step of carcinoma metastasis, in which epithelial cells lose cell-cell adhesion, gain motility, and invade into adjacent stroma. Subsequent steps of metastasis include vascular intravasation and extravasation, establishment of a metastatic niche, and angiogenesis. Tumor invasiveness, the morphologic characteristic that distinguishes BAC from AC, is determined by the interaction of tumor cells with the surrounding stroma.

We16 and others17–20 have used microarray gene expression profiling of lung AC to identify signatures associated with histology and invasion. The results of unsupervised analyses, in which the specimens are sorted into groups in a dendogram based on similarity of gene expression, show lung ACs segregate into three major branches comprised predom-
mutations in pancreatic and oropharyngeal carcinomas.\textsuperscript{21–23} The inhibitory effects of TGF-\(\beta\)-RII repression was required for lung AC invasion, is supported by genetic models combining targeted deletion of TBFRII with other oncogenic events such as adenomatosis polyposis coli mutation in colon tumors and KRAS mutations in pancreatic and oropharyngeal carcinomas.\textsuperscript{21–25} The phenotypes of these TGF-\(\beta\) receptor cancer models clearly demonstrate the importance of TGF-\(\beta\) signaling in tumor invasion.

TGF-\(\beta\), the ligand for the TGF-\(\beta\) type II receptor is a pleiotropic cytokine comprised of family members TGF-\(\beta\) 1, 2, and 3 that regulate tissue homeostasis and prevent tumor initiation by inhibiting cellular proliferation, differentiation, and survival.\textsuperscript{24} It is secreted as a latent molecule and is activated by cleavage by proteases and other molecules.\textsuperscript{25} Signaling primarily occurs through SMAD protein dependent pathways whereby ligand binding to TBFRII induces phosphorylation and activation of TGF-\(\beta\) type I receptor (TBFRI). After interaction with TBFRI, phosphorylated SMAD2 and SMAD3 dissociate to form a heterotrimeric complex with SMAD4 and translocate into the nucleus to regulate gene transcription (Fig. 1A). TGF-\(\beta\) signaling may also proceed via less well-understood SMAD independent pathways (Fig. 1B). These “noncanonical” pathways involve various signaling cascades including Ras/ERK, Rho/ROCK, and TAK1/MAPK and are likely to have important roles in mediating the protumorigenic effects of TGF-\(\beta\).\textsuperscript{26} Depending on context, TGF-\(\beta\) signaling may alternatively function to suppress tumor growth or to promote tumor cell invasion and metastasis.\textsuperscript{27–30}

**TGF-\(\beta\) as a Tumor Suppressor**

Although recent research has focused primarily on TGF-\(\beta\) receptor alterations, tumors may use various mechanisms anywhere along the signaling cascade to circumvent the inhibitory effects of TGF-\(\beta\).\textsuperscript{31–35} Type II receptor genetic alterations are well characterized in gastrointestinal tumors in which 25\% of colorectal carcinomas have missense mutations associated with microsatellite instability. Animals with targeted deletion of TBFRII in the colonic epithelium demonstrate increased tumor progression from adenomas to invasive carcinomas\textsuperscript{36} similar to human colorectal tumors with loss of type II receptor.\textsuperscript{17} In breast carcinoma models, mammary tumors in animals with targeted deletion of TBFRII demonstrated increased progression and metastases.\textsuperscript{38} A recent case-control study in human breast tumors indicated that within breast hyperplasia specimens, the proportion of cells with decreased type II receptor immunostaining was associated with increased risk for the development of invasive breast cancer.\textsuperscript{39} Multiple lung cancer cell lines, both small cell\textsuperscript{40–42} and non-small cell,\textsuperscript{43–46} demonstrate reduced expression TGF-\(\beta\)RII. This repression is accompanied by marked reductions in TGF-\(\beta\) mediated growth suppression which is rescued after restoration of the receptor. In human lung tumor specimens, type II receptor repression is evident in approximately 40\% of lung ACs overall and in up to 100\% of poorly differentiated ACs.\textsuperscript{47} Mechanisms of repression include epigenetic silencing,\textsuperscript{48} microsatellite instability, and frameshift mutations involving the poly(A) tract.\textsuperscript{43} For the TGF-\(\beta\) type I receptor, mRNA repression is detectable in non-small cell lung cancer,\textsuperscript{49} and recent studies indicate that TBFRI mRNA SNP variants are associated with an increased risk of lung cancer.\textsuperscript{50–52}

**TGF-\(\beta\) as a Tumor Promoter**

Several tumors, including those arising in the lung\textsuperscript{53–55} express high levels of the TGF-\(\beta\), which correlates with tumor progression and clinical prognosis.\textsuperscript{34,56–60} TGF-\(\beta\) signaling promotes epithelial to mesenchymal transition, a characteristic of invasive and metastatic cells,\textsuperscript{61,62} with constitutive activation of TGF-\(\beta\) or TBFRII leading to increased metastases in animal models of breast cancer.\textsuperscript{53–65} Similarly, blockade of TGF-\(\beta\) signaling via either dominant negative expression of SMAD3 or defective TBFRI leads to decreased lung metastases.\textsuperscript{66,67} Systemic inhibition of TGF-\(\beta\) has been shown to suppress metastasis\textsuperscript{68–71} and TGF-\(\beta\) overexpression by non-small cell lung cancer specimens was found by multivariate analysis to be an independent risk factor for pulmonary metastasis.\textsuperscript{72}

How do we reconcile these findings with those suggesting TGF-\(\beta\) is a tumor suppressor? Context dependency in terms of cell type, tumor stage, and mode of inhibition of TGF-\(\beta\) signaling are important. Other important issues are the degree of repression of TGF-\(\beta\) receptor levels and the stromal response to TGF-\(\beta\) signaling inhibition. Rojas et al.\textsuperscript{73} have shown that different levels of repression of the TGF-\(\beta\) receptor are associated with differences in the activation of the SMAD and MAPK pathways such that at lower levels of TGF-\(\beta\) receptor activation, the protumorigenic non-SMAD signaling pathways dominate. Yang et al. showed that targeted deletion of TBFRII in the mammary epithelium promoted breast cancer metastases through the CXCL5/CXCR2 chemokine axis mediated recruitment of Gr-1\textsuperscript{+}/CD11b\textsuperscript{+} myeloid derived suppressor cells.\textsuperscript{74} Increased stromal TGF-\(\beta\) levels at the invasive front of tumors was shown to be important for tumor progression and for inhibition of tumor immunosurveillance.\textsuperscript{74}

**Chemokine Signaling in Human Tumors with Repressed TBFRII Expression—CCL5**

Our results in lung AC and in in vitro systems indicate that repression of the TGF-\(\beta\) type II receptor increases
We have shown that activation of SMAD2 and Akt are lower in TβRII knockdown cells, whereas p38 activation is slightly increased. We expect that TGF-β signaling may also proceed via SMAD-independent pathways that involve various signaling cascades including Ras/ERK, Rho/ROCK, and TAK1/MAPK. These noncanonical pathways are likely to have important roles in mediating the protumorigenic effects of TGF-β. C, The histologic distinction between bronchioalveolar carcinoma (BAC) and other adenocarcinomas is tissue invasion. Invasion requires loss of cell-cell adhesion, migration, membrane degradation with vascular intravasation and extravasation, establishment of the metastatic niche angiogenesis and recruitment of stromal elements (top panel). We have shown that repression of TGF-β type II receptor in lung adenocarcinoma cells increases invasiveness and have used microarray analyses and inhibitor studies to identify the CC chemokine RANTES as an important mediator of lung adenocarcinoma invasion in TβRII-deficient tumors. Reprinted with permission from Borczuk AC, Toonkel RL, Powell CA. Genomics of lung cancer. Proceedings of the American Thoracic Society 2009;6:152–158. Official Journal of the American Thoracic Society. © American Thoracic Society.81

Among potential mediators identified was the CC (or β-chemokine) family member CCL5 (regulated on activation, normal T cell expressed, and presumably secreted [RANTES]), which was up-regulated by invasive tumors and TβRII knockdown cells. RANTES is involved in immunoregulatory and inflammatory processes and is secreted by T cells and other inflammatory cells, stromal cells, as well as tumor cells and...
normal bronchial epithelium. RANTES is a ligand for chemokine receptors CCR1, CCR3, CCR4, and CCR5, which are expressed on epithelial cells, macrophages, lymphocytes, dendritic cells, andstromal cells.\textsuperscript{76–79} Inhibition of RANTES signaling significantly abrogates tumor invasion, suggesting that RANTES is required for invasion in TGF-β type II receptor repressed lung AC cells (Fig. 1C). The clinical significance of this pathway is further supported by the finding that tumor expression of RANTES and CCR5 in lung AC is associated with patient survival.\textsuperscript{80} Small molecule inhibitors of CCR5 may have the potential to treat and prevent lung AC. Taken together, these studies illustrate how information gained from global expression profiling of tumors can be used to identify key pathways and genes mediating tumor growth, invasion, and metastasis.

REFERENCES

39. Dobhi H, Dupont WD, Simpson JF, et al. Transforming growth factor-


